Skip to content
RDL Network logo
Combination of avelumabwith peptide receptor radionuclide therapy (PRRT) or conventional fractionated radiotherapy (RT) in metastatic merkel cell carcinoma (mMCC) [GoTHAM study] — Shahneen Sandhu (2019) | RDL Network